<DOC>
	<DOCNO>NCT02974647</DOCNO>
	<brief_summary>The purpose study test good bad effect study drug call ruxolitinib . Ruxolitinib work block protein call JAK . JAK work along another protein call STAT important survival many T NK-cell lymphoma . By block JAK , ruxolitinib may cause T NK-cell lymphoma shrink .</brief_summary>
	<brief_title>Study Ruxolitinib Relapsed Refractory T NK Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Pathologically confirm T NK cell lymphoma enrol institution . For CTCL , patient stage IB disease great eligible . Relapse refractory disease least 1 systemic therapy Age ≥ 18 ECOG ≤ 2 Measurable disease define : Lugano Classification systemic lymphoma Absolute atypical lymphocyte ≥ 1000 cells/μL disease characterize leukemic disease mSWAT &gt; 0 Sezary count ≥ 1000 cells/μL CTCL Previous systemic anticancer therapy must discontinue least 2 week prior treatment . Glucocorticoids aim control lymphomarelated symptom allow long tapered 20mg less time ruxolitinib initiation . Topical steroid CTCL permit . Patients must meet follow lab criterion : ANC ≥ 1.0/mm^3 , platelet ≥ 100 x 10^9/L ≥ 75 x 10^9/L ( related lymphoma ) , Hgb ≥ 8g/dL Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) ; ≤ 3 x ULN due lymphoma involvement ; AST ALT ≤ 3 x ULN ; ≤ 5 x ULN due lymphoma involvement Creatinine clearance ≥ 30 mL/min For patient positive hepatitis B core antibody surface antigen , hepatitis B PCR must negative prophylaxis entecavir equivalent require . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . Uncontrolled concurrent illness include , limited , ongoing active infection , uncontrolled diabetes , clinically significant pneumonitis , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . ECOG performance status &gt; 2 Prior therapy ruxolitinib Concurrent use anticancer agent treatment . °Patients one type lymphoma may enrol discussion MSK Principal Investigator Known history test positive human immunodeficiency virus ( HIV ) know acquired immunodeficiency syndrome ( AIDS ) within 12 month prior initiate study treatment . Women reproductive potential† must negative Serum ß human chorionic gonadotropin ( ßHCG ) pregnancy test . A female reproductive potential sexually mature female : undergone hysterectomy bilateral oophorectomy ; naturally postmenopausal least 24 consecutive month ( i.e . menses time precede 24 consecutive month ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Ruxolitinib</keyword>
	<keyword>T NK Cell</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
</DOC>